Source: Annual Congress 2001 - Small cell lung cancer therapy
Disease area: Interstitial lung diseases, Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
M. Tondini, P. A. Chini, D. Corbellini, A. Merizzi, P. Mercurio, L. Salada, F. Speciale, D. Sereni (Esine, Sondalo, Italy). Sequential monochemotherapy: vepesid (VP16) and carboplatin (CBDCA) in the treatment of elderly patients with small cell lung cancer (SCLC). Eur Respir J 2001; 16: Suppl. 31, 2695

Member's Comments

No comment yet.

Related content which might interest you: Low dosage chemotherapy, with carboplatin (CBDCA) and vinorelbine (VNR), in advanced nonsmall cell lung cancer (NSCLC) in patients with low performance status Source: Eur Respir J 2003; 22: Suppl. 45, 528s Year: 2003 Treatment of advanced and metastatic non small cell lung carcinoma (NSCLC) with a new schedule of gemcitabine (GEM) plus cisplatin (CDDP) Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002 A Phase II study of induction carboplatin (CBDCA) and docetaxel (DOC) with concurrent radiation in early-stage non-small cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003 Gemcitabine plus vinorelbine (GV) or paclitaxel (GT) versus gemcitabine (G) or paclitaxel (T) alone in elderly or unfit nonsmall cell lung cancer (NSCLC) patients. SICOG 9909 phase III trial Source: Eur Respir J 2003; 22: Suppl. 45, 527s Year: 2003 A comparison between the toxic side effects of adriamycin, cyclophosphamide, and etoposide (ACE) and carboplatin with etoposide (CbE) in the treatment of small cell lung cancer (SCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 65s Year: 2003 Economic evaluation of gemcitabine plus cisplatin (GD) versus vinorelbine plus cisplatin plus Ifosfamide (NIP) in patients with locally advanced or metastatic non-small-cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 29s Year: 2003 Different efficacy between carboplatin (Cpl) and gemcitabine (Gem) on median survival time of elderly non small cell lung cancer (NSCLC) patients Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005 A phase 2 study of induction carboplatin (CBDCA) and dosetaxel (DOC) with concurrent radiation in early-stage non-small cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 375s Year: 2001 Gemcitabine and carboplatin (GC) versus mitomycin, ifosfamide and cisplatin (MIP): a phase III randomised comparison in stage IIIb or IV non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 399s Year: 2002 Gemcitabine and cisplatin ( GD) as first line chemotherapy in patients with non-small-cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002 Gemcitabine, ifosfamide and paclitaxel in patients with untreated advanced/metastatic nonsmall cell lung cancer (NSCLC) A phase II study Source: Eur Respir J 2003; 22: Suppl. 45, 28s Year: 2003 First line treatment with gemcitabine plus cisplatine in non-small cell lung cancer: a comparison with etoposide plus cisplatin Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005 Docetaxel as second-line chemotherapy (CT) in advanced non small cell lung cancer(NSCLC) patients (pts): does it really work? Source: Eur Respir J 2003; 22: Suppl. 45, 31s Year: 2003 Ifosfamide (IFO) is a valuable alternative to cisplatin (CDDP) for first-line chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC): A meta-analysis Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013 Docetaxel (DOC) and gemcitabine (GEM) consist a safe and effective combination in the management of non-small cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 30s Year: 2003 A phase I trial of combined carboplatin and topotecan as 2nd line treatment in patients (pts) with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 30s Year: 2003 Carboplatin (C), paclitaxel (T) and etoposide (E) and early concurrent thoracic radiotherapy (TRT) for patients with limited disease small cell lung cancer (LD-SCLC): a Dutch multicentre phase 2 study Source: Eur Respir J 2002; 20: Suppl. 38, 187s Year: 2002 Effectivity of chemotherapy regimen included carboplatin, ifosfamide, etoposide with or without adding interferon alpha 2a in treatment of patients with small cell lung carcinoma Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005 Once a day (QD) thoracic radiotherapy (XRT) for patients with limited stage small-cell lung cancer (SCLC) treated concurrently with etoposide and cisplatin (EP): results of a single institution retrospective experience Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology Year: 2007 A phase III randomised study comparing concomitant standard cisplatin (P) – etoposide (E) and chest irradiation to concomitant etoposide plus daily cisplatin and chest irradiation as induction therapy for limited (LD) small cell lung cancer (SCLC) Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008